Japan’s Nippon Chemiphar saw its operating profit more than halved and a 4% drop in year-on-year generics sales in the first nine months of its financial year ending 31 March 2020, as the company said it was “unable to compensate for the impact of National Health Insurance drug price revisions implemented in October 2019.”
Nippon Chemiphar reported generics sales down by 4% to ¥20.61bn ($187m) for the first nine months of the financial year,...






